Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTAMedical - Care Facilities
+$0.00 today
- Market cap
- $445.55M
- Beta
- 0.00
- P/E (TTM)
- 414.6
- EPS (TTM)
- $0.07
Volume 0.00M
Average 0.87M
MCTA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Charming Medical Limited Class A Ordinary SharesNASDAQ: MCTA
Free Cash Flow · FY2024 · year ended Mar 2025
Free cash flow grows 63.1% year over year
FY2024 free cash flow of $138.36K rose 63.1% year over year.
Context
- Free cash flow amounted to 2.2% of revenue in FY2024, up 0.8 pp from a year earlier.
- Free cash flow increased in 1 of the last 2 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2024
- 138.36K USD
- Year-over-year change
- +63.1%
- 2-year CAGR
- -72.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2024 | 2025-03-31 | 138.36K | +63.1% |
| FY2023 | 2024-03-31 | 84.83K | -95.4% |
| FY2022 | 2023-03-31 | 1.83M | — |
Free Cash Flow vs competitors
How MCTA compares with its peers on the latest reported figures
- MCTA's FY2024 free cash flow of $138.36K is the smallest of the 10 companies compared; the peer median is $21.58M.
- Its year-over-year change of +63.1% is the 4th highest of 10, against a peer median of +30.9%.
- Free cash flow amounts to 2.2% of revenue for MCTA, versus a peer median of 14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $183.16M | +30.9% | +14.9% | — | |
| LTM Mar 2026 | $76.61M | +26.2% | -10.0% | 1.3% | |
| LTM Mar 2026 | $45.99M | +1079.1% | +272.9% | 1173.4% | |
| LTM Mar 2026 | $39.6M | -64.4% | -31.6% | 4.0% | |
| LTM Mar 2026 | $39.22M | +3.9% | +130.8% | 11.4% | |
| LTM Mar 2026 | $25.73M | +34.3% | -25.5% | 4.7% | |
| LTM Feb 2026 | $22.87M | +130.8% | +7.7% | 28.4% | |
| LTM Mar 2026 | $21.58M | +5.2% | -31.9% | 16.9% | |
| LTM Mar 2026 | $19.19M | +353.2% | — | 21.2% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $138.36K | +63.1% | — | 2.2% |
| Peer median (excluding MCTA) | $21.58M | +30.9% | -1.2% | 14.2% | |
Competitors are the stored peer set for MCTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 |
|---|---|---|---|
| Net Income | (335.61K) | 821.74K | 1.2M |
| Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
| Deferred Income Tax | 0 | 62.48K | 134.87K |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 2.5M | (943.05K) | (1.16M) |
| Accounts Receivables | (154.02K) | (164.98K) | (44.29K) |
| Inventory | (55.87K) | 38.18K | 1.35K |
| Accounts Payables | 180.4K | 210.28K | (204.69K) |
| Other Working Capital | 2.53M | (1.03M) | (913.02K) |
| Other Non-Cash Items | 60.9K | (37.45K) | (10.89K) |
| Operating Cash Flow | 2.43M | 295.43K | 425.89K |
| Capital Expenditures | (606.19K) | (210.6K) | (287.53K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.94M) |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (606.19K) | (210.6K) | (2.23M) |
| Debt Repayment | (177.92K) | (115.85K) | 48.93K |
| Common Stock Issued | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (1.25M) | 216K | 472.37K |
| Financing Cash Flow | (1.43M) | 100.15K | 521.3K |
| Effect of Forex Changes | 5.66K | (10.51K) | (4.62K) |
| Net Change in Cash | 402.99K | 174.46K | (1.29M) |
| Free Cash Flow | 1.83M | 84.83K | 138.36K |
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
Intrinsic Alpha fair value
Locked
Current Price
$29.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.